glp-1 agonists tirzepatide Unveiling Tirzepatide's Therapeutic Spectrum: A Dual GIP/GLP-1 Agonist Targeting Metabolic, Neurological, and Cardiovascular Health Pharmacogenomics of Tirzepatide: Genomic Insights

Post-Injection Protocol: Always remove and safely discard the needle after every use

Clinician-supervised metabolic optimization

Weeks 17-20

A combination of plant-based products designed to supplement the nutritional needs of weight-loss drug patients, including those on a GLP-1.

This comprehensive GLP-1 Travel Guide covers everything you need to know to keep your medication safe, stay compliant with regulations, and maintain your treatment schedule wherever your journey takes you.

Results Over the course of the last year in the overall- and paired populations there was an increase in BMI (median [IQR] 25.7 [22.8-30.0] to 26.7 [23.8-31.1] kg/m2, p=6.4x10-5 and 26.8 [23.4-31.7] to 27.1 [23.8-31.8] kg/m2, p=3.7x10-4, respectively) and overweight and obesity ([figure 1A][1])